Cardiology's New Frontier: A Bold Partnership to Tackle Sleep Apnea

LITTLETON, CO – June 10, 2026 – In a move that signals a significant shift in treating comorbid health conditions, medical technology firm Vivos Therapeutics has announced a landmark collaboration with South Palm Cardiovascular Associates (SPCVA), a major Florida cardiology group. The partnership will establish AIM Florida, a new entity designed to integrate the diagnosis and treatment of obstructive sleep apnea (OSA) directly into the patient care pathway for cardiovascular disease. This venture isn't just about a new service line; it represents a strategic pivot towards a more holistic, and potentially highly profitable, model of healthcare delivery that could set a new standard nationwide.

For Vivos, a company focused on innovative treatments for breathing-related sleep disorders, the alliance provides direct access to one of the highest-risk patient populations: the roughly 30,000 individuals on record with SPCVA. For cardiologists, it offers a streamlined solution to a pervasive and dangerous comorbidity that often complicates patient outcomes. And for patients, it promises to close a dangerous gap in the healthcare system, bringing treatment for a silent killer out of the shadows and into the mainstream of cardiac care.

A New Blueprint for Integrated Care

The structure of the deal is as innovative as its clinical premise. Vivos will hold a majority stake (not less than 80%) in AIM Florida, a physician-aligned management services organization (MSO), with SPCVA holding the remainder. This model is a deliberate evolution of Vivos' strategy, building on lessons from its June 2025 acquisition of Sleep Centers of Nevada (SCN). While the SCN purchase gave Vivos a direct-to-patient revenue stream, it came with significant capital outlay. The AIM Florida partnership, by contrast, is designed for capital efficiency.

R. Kirk Huntsman, Chairman and CEO of Vivos, highlighted this strategic shift in the announcement. "The key difference here is that we are partnering directly with the medical community without incurring the significant capital outlays required in an acquisition," he stated. "By creating a true collaboration with fully aligned interests, all parties expect to raise the standard of care for patients who suffer from both OSA and CVD."

This MSO model effectively embeds a specialized 'Sleep Optimization Team' within the cardiology practice, creating a turnkey solution. It addresses a critical bottleneck in the healthcare system: a recognized national shortage of board-certified sleep medicine specialists. Instead of referring patients out to a fragmented system of sleep labs and specialists—a process that can take months and lead to high patient drop-off—SPCVA cardiologists can now direct them to an in-house, integrated service. Vivos plans to initially deploy one team in the Palm Beach County market, with ambitions to scale the model across Florida and eventually to the more than 2,500 similar cardiology groups nationwide.

The Silent Threat in the Bedroom

The clinical urgency behind this partnership cannot be overstated. Obstructive sleep apnea, a condition affecting over a billion people worldwide, is far more than a simple snoring problem. It is an independent risk factor for cardiovascular events and mortality. Research indicates an alarmingly high prevalence of OSA in cardiac patients—as many as 40% to 80% of individuals with conditions like hypertension, heart failure, and atrial fibrillation also suffer from it. When breathing repeatedly stops and starts during sleep, it starves the body of oxygen and puts immense strain on the cardiovascular system.

Cardiologists have long been aware of this dangerous link, but effective, integrated treatment has remained elusive. The traditional pathway often fails, leaving a vast population of high-risk patients undiagnosed and untreated. The dominant treatment, the Continuous Positive Airway Pressure (CPAP) machine, suffers from notoriously low compliance rates, with some studies suggesting up to 50% of patients abandon the therapy. This is where Vivos sees its opening.

The company's flagship 'Vivos Method' utilizes custom-fitted, non-invasive oral appliances. These devices have received FDA 510(k) clearance for treating all severity levels of OSA in adults. Unlike appliances that simply reposition the jaw during sleep, Vivos claims its technology works to remodel the upper airway, offering a potential long-term solution. By embedding this alternative treatment directly within the cardiology clinic, AIM Florida aims to improve patient access and adherence, thereby mitigating the cardiovascular risks associated with untreated OSA.

The Business of Breathing Easier

While the clinical promise is clear, the financial architecture of the deal reveals Vivos' ambition to transform its business model. The company projects that a single, fully deployed Sleep Optimization Team can generate over $6,000,000 in annual revenue with contribution margins approaching 50%. These are bold figures, benchmarked against the performance of the SCN acquisition, which demonstrated the revenue potential of a direct-care model.

This strategy comes at a critical time for Vivos. The company has shown strong revenue growth, with Q1 2026 revenue hitting $5.1 million, a significant increase from the prior year. However, it has also faced persistent net losses and recent NASDAQ compliance challenges. The AIM Florida model represents a calculated push toward profitability by capturing higher-margin service revenue with minimal upfront investment. If successful, this capital-efficient, scalable partnership blueprint could provide a clear path to positive cash flow and long-term growth.

The scalability is the key. Success in Palm Beach County will serve as the proof-of-concept for a national rollout. Convincing thousands of other cardiology and specialty medical practices to adopt the model will require demonstrable clinical and financial results, but the underlying market need is undeniable.

Navigating a Complex Healthcare Landscape

Forging such a deep financial and operational link between a medical device company and a physician practice requires careful navigation of a complex regulatory environment. The structure of any MSO must be meticulously designed to comply with federal Anti-Kickback Statutes and physician self-referral laws (Stark Law), which prohibit financial arrangements intended to induce patient referrals. The press release explicitly states that all clinical decisions and patient care protocols will remain exclusively under the authority of licensed healthcare professionals, a necessary firewall to ensure compliance.

By partnering with an established and respected cardiology group like SPCVA, Vivos gains immediate credibility and patient flow. In the competitive Florida market, which features numerous hospital-affiliated sleep centers and independent providers, this integrated model serves as a powerful differentiator. It moves the point of care for a critical comorbidity from a separate specialty to the primary point of cardiovascular treatment, creating a streamlined, patient-centric experience that competitors will find difficult to replicate.